Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies-Reference-Cited by-同舟云学术

Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies

Published:2022-08-13 Issue:2 Volume:72 Page:493-507
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Wang Jie,Li Chen,He Kaijie,Kuang Zhihui,Lu Jia,Yao Ying,He Fufan,Li Ninghuan,Li Li,Fu Fenggen,Wu Zhihai,Zhou Shuaixiang,Kang Dian,Qiu Xuan,Wu Min,Liu Yang,Cao Xiaochao,Xu Mengqiu,Chen Bingliang,Wu Weiwei,Guo Feng

Funder

Innovent Biologics

Suzhou Municipal Science and Technology Bureau

Jiangsu Commission of Health

Special Technical Project of Diagnosis and Treatment of Key Clinical Diseases of Suzhou

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-022-03267-5.pdf

Reference39 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33. https://doi.org/10.3322/caac.21654

2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132. https://doi.org/10.3322/caac.21338

3. Ghielmini M (2005) Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example. Hematol Am Soc Hematol Educ Program. https://doi.org/10.1182/asheducation-2005.1.321

4. Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380:848–857. https://doi.org/10.1016/S0140-6736(12)60605-9

5. Casulo C, Byrtek M, Dawson KL et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol 33:2516–2522. https://doi.org/10.1200/JCO.2014.59.7534

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma;American Society of Clinical Oncology Educational Book;2024-06

2. The present and future of bispecific antibodies for cancer therapy;Nature Reviews Drug Discovery;2024-03-06

3. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma;OncoImmunology;2024-03-03

4. Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment;Cancer Immunology, Immunotherapy;2023-09-14

5. The NR_109/FUBP1/c-Myc axis regulates TAM polarization and remodels the tumor microenvironment to promote cancer development;Journal for ImmunoTherapy of Cancer;2023-05